{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002570","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.889935+00:00","generated_at":"2026-06-02T22:36:02.065136+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Celldex reports Q1 net loss $32.8M; cash $823.8M; Phase 3 CSU studies planned summer 2024","bullets":["Net loss of $32.8M ($0.56 per share) vs $29.4M ($0.62) in Q1 2023; revenue $0.2M.","Cash, cash equivalents and marketable securities $823.8M, up from $423.6M due to $432.3M net public offering.","Phase 3 CSU studies to initiate summer 2024; 52-week Phase 2 CSU data expected H2 2024.","Phase 2 CIndU enrollment completed (196 patients); 12-week data due H2 2024.","Atopic dermatitis selected as fifth indication; Phase 2 study to start by year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002570","json":"https://secwatch.observer/filing/0001171843-24-002570.json","markdown":"https://secwatch.observer/filing/0001171843-24-002570.md","text":"https://secwatch.observer/filing/0001171843-24-002570.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184324002570/0001171843-24-002570-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184324002570/f8k_050624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:36:02.065136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af389b545e7509c1f6ce524d598c4d096c81b950","claim":"Celldex Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 6, 2024, Celldex Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the first quarter of 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744218/000117184324002570/0001171843-24-002570-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}